Table 1.
Clinical trials of PD-1/PD-L1 inhibitors in human cancers.
| Inhibitors | Style | Cancers | Trial number | N | OS | ORR | PFS | References | |
|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | PD-1 | Gastric cancer | NCT02589496 | 61 | N/A | 85.7% in microsatellite instability-high mGC | 100% in Epstein-Barr virus-positive mGC | N/A | (56) |
| Pancreatic cancer | NCT02054806 | 475 | N/A | 0.0% to 14.2% | 1.7 months 1.5 to 2.9 months) | (57) | |||
| Small-cell lung cancer | N/A | 33% (15.6% to 55.3%) | N/A | ||||||
| Thyroid cancer | N/A | N/A | 6.8 months (1.9 to 14.1 months) | ||||||
| Non-Small-Cell Lung Cancer | NCT02142738 | 305 | N/A | N/A | 10.3 months | (58) | |||
| Breast cancer | NCT02447003 | 84 | 18 months | 2.1 months | (59) | ||||
| Non-small-cell lung cancer | NCT02775435 | 559 | 15.9 VS 11.3 months (pembrolizumab-combination group VS placebo-combination group) | N/A | ( 6.4 VS 4.8 months pembrolizumab- combination group VS placebo-combination group) | (60) | |||
| Gastric cancer | NCT01848834 | 39 | N/A | 22% | N/A | (61) | |||
| Non-small-cell lung cancer | NCT01295827 | 495 | 12 months | 19.40% | 3.7 months | (62) | |||
| Melanoma | NCT01295827 | 655 | N/A | 8%, 12%, 22%, 43%, 57%, and 53% for MEL scale of 0, 1. 2, 3, 4 and 5 | N/A | (1) | |||
| Hepatocellular carcinoma | NCT02702414 | 104 | N/A | 17% | N/A | (63) | |||
| Malignant pleural mesothelioma | NCT02054806 | 25 | N/A | 20% | N/A | (64) | |||
| Nivolumab | PD-1 | Advanced hepatocellular carcinoma | NCT01658878 | 262 | N/A | 20% | N/A | (63) | |
| Hodgkin Lymphoma | NCT02181738 | 80 | N/A | 66.30% | N/A | (65) | |||
| ovarian cancer | NCT02873962 | 38 | N/A | 40% in platinum-sensitive and 16.7% in platinum- resistant participants | 8.1 months | (66) | |||
| Follicular lymphoma | NCT01592370 | 10 | 40% | N/A | (67) | ||||
| Diffuse large B- cell lymphoma | 11 | N/A | 36% | N/A | |||||
| Peripheral T-cell lymphoma | 5 | N/A | 40% | N/A | |||||
| Melanoma | NCT01844505 | 945 | N/A | N/A | 11.5 VS 2.9 months(nivolumab plus ipilimumab group VS ipilimumab alone group) | (68) | |||
| Atezolizumab PD-L1 | PD-1 | Triple-Negative Breast Cancer | NCT02425891 | 451 | 21.3 VS 17.6 months(atezolizumab plus nab- paclitaxel group VS placebo plus nab- paclitaxel group) | N/A | 7.2 VS 5.5 months(atezolizumab plus nab-paclitaxel group VS placebo plus nab- paclitaxel group) | (69) | |
| Non-small-cell lung cancer | NCT02008227 | 1225 | 15.7VS 10.3 months (atezolizumab group VS docetaxel group) | N/A | N/A | (70) | |||
| Toripalimab | PD-1 | Alveolar soft part sarcoma | NCT02836834 | 12 | 34.7 months | 22.70% | 5.7 months | (71) | |
| Lymphoma | 11 | N/A | 90.90% | 8.3 months | |||||
| Non-Small Cell Lung Cancer | NCT03301688 | 41 | 13. 8 months among 28 patients included in the response and survival analysis | N/A | 2.8 months among 28 patients included in the response and survival analysis | (72) | |||
| Durvalumab PD-L1 | Head and neck squamous cell carcinoma | NCT02207530 | 112 | 7.1 months | N/A | 2. 1 months | (12) | ||
| Non-Small Cell Lung Cancer | 406 | 13.- months; 3.4 VS16.2 months (HPD VS Non-HPD) | 18.90% | 2.1 months | (73) | ||||
| Avelumab | PD-L1 | Metastatic breast cancer | NCT01772004 | 168 | N/A | 3.0% overall | 5.2% in patients with TNBC | N/A | (74) |
| Tislelizumab | PD-1 | Hodgkin lymphoma | NCT03209973 | 70 | N/A | 87.10% | 74.5% (9-month progression-free survival rate) | (75) | |
| Camrelizumab | PD-1 | Hodgkin lymphoma | NCT03155425 | 75 | N/A | 76.00% | N/A | (76) | |
| GLS-010 | PD-1 | Hodgkin lymphoma | NCT03713905 | 24 | N/A | 87.50% | N/A | (77) | |
| Peripheral NK T lymphoma | 14 | N/A | 21.4% | N/A | |||||
N/A, Not Applicable.